However, because all of the enrolled patients with ASCVD had type 2 diabetes, further high-quality studies are needed to evaluate the efficacy of SGLT2 inhibitors in patients with ASCVD who do not have diabetes. This evidence concerns the gene SLC5A2 and atherosclerosis.